| |
Placebo
(N=32) |
5mg CCX140-B
(N=63) |
10mg CCX140-B
(N=32) |
30mgPioglitazone
(N=32) |
All
(N=159) |
| Mean ± SD age—yr |
58.5 ± 8.02 |
58.8 ± 6.36 |
57.5 ± 5.51 |
60.0 ± 6.36 |
58.7 ± 6.56 |
| Male—no. (%) |
20 (62.5) |
40 (63.5) |
21 (65.6) |
20 (62.5) |
101 (63.5) |
Race—no. (%)
Caucasian
Asian
Black/African
Other |
32 (100.0)
0
0
0
|
62 (98.4)
1 (1.6)
0
0
|
30 (93.8)
1 (3.1)
0
1 (3.1)
|
31 (96.9)
0
1 (3.1)
0
|
155 (97.5)
2 (1.3)
1 (0.6)
1 (0.6)
|
| Mean ± SD body mass index—kg/m2) |
32.4 ± 4.04 |
32.3 ± 4.58 |
32.1 ± 4.30 |
31.3 ± 4.68 |
32.1 ± 4.42 |
| Mean ± SD waist circumference—cm |
107.8 ± 11.56 |
107.7 ± 12.59 |
106.7 ± 13.21 |
105.3 ± 10.83 |
107.1 ± 12.12 |
| Mean ± SD diabetes duration—months |
81.0 ± 60.41 |
83.7 ± 66.43 |
75.3 ± 57.91 |
89.4 ± 52.62 |
82.6 ± 60.58 |
| MCP-1 base pair at -2518 position = GG or AG—no. (%) |
14 (43.8%) |
30 (47.6%) |
15 (46.9%) |
15 (46.9%) |
74 (46.5%) |
| Mean ± SD FPG—mg/dL |
182.9 ± 52.95 |
166.0 ± 34.23 |
163.1 ± 37.08 |
169.8 ± 40.40 |
169.6 ± 40.61 |
| Mean ± SD fasting insulin—mIU/L |
18.0 ± 11.86 |
16.6 ± 16.18 |
17.9 ± 17.48 |
13.5 ± 8.27 |
16.5 ± 14.38 |
| Mean ± SD total adiponectin—mg/mL |
6.4 ± 3.67 |
6.2 ± 3.34 |
6.4 ± 2.73 |
6.2 ± 3.58 |
6.2 ± 3.32 |
| Mean ± SD HOMA-IR |
8.5 ± 6.62 |
7.2 ± 8.64 |
7.3 ± 7.00 |
5.7 ± 3.49 |
7.2 ± 7.14 |
| Mean ± SD HbA1c— % |
7.6 ± 1.00 |
7.4 ± 0.74 |
7.3 ± 0.81 |
7.6 ± 0.86 |
7.5 ± 0.83 |
| Mean ± SD fructosamine— μmol/L |
291.6 ± 51.60 |
285.3 ± 36.48 |
286.3 ± 43.47 |
289.6 ± 36.05 |
287.6 ± 40.87 |
| Mean ± SD plasma MCP-1—pg/mL |
444.9 ± 129.72 |
432.0 ± 138.35 |
383.8 ± 78.19 |
420.7 ± 81.13 |
423.0 ± 117.87 |
| Mean ± SD C-reactive protein— mg/L |
4.3 ± 6.00 |
6.3 ± 11.63 |
3.2 ± 2.91 |
6.9 ± 9.58 |
5.4 ± 9.11 |
